Liposomes as carriers for vaccines.
A liposome vaccine formulation that has been successfully used in both animal immunization studies and clinical trials is described. Issues concerning the choice of components for the liposomal vaccine formulation are discussed, especially with respect to the lipid components and the adjuvant. A procedure is described for manufacturing liposomal vaccines using Good Manufacturing Practices as promulgated by the U.S. Food and Drug Administration. Quality control testing for clinical use is described, with particular emphasis on aspects relevant to liposomes. Utilization issues are discussed, including injection volumes, antigen and adjuvant doses, and routes of administration.
Wassef
N M
NM
Department of Membrane Biochemistry, Walter Reed Army Institute of Research, Washington, District of Columbia 20307-5100.
Alving
C R
CR
Richards
R L
RL
D016915:AIDS Vaccines / Q000008:administration & dosage; D000276:Adjuvants, Immunologic; D000534:Alum Compounds; D000818:Animals; D002986:Clinical Trials as Topic; D004339:Drug Compounding; D000882:Haplorhini; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008050:Lipid A / Q000276:immunology; D008081:Liposomes / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D017780:Malaria Vaccines / Q000008:administration & dosage; D051379:Mice; D010963:Plasmodium falciparum / Q000276:immunology; D011786:Quality Control; D011817:Rabbits; D018449:SAIDS Vaccines / Q000008:administration & dosage; D012449:Safety; D014611:Vaccination / Q000379:methods; D014612:Vaccines / Q000008:administration & dosage
D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D000534:Alum Compounds; D008050:Lipid A; D008081:Liposomes; D017780:Malaria Vaccines; D018449:SAIDS Vaccines; D014612:Vaccines; C041524:aluminum sulfate